MDxHealth Licenses Methylation Technology to Takara | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today said that it has licensed to Takara Bio non-exclusive worldwide rights to its methylation-specific PCR technology.

Japan-based Takara has licensed the technology for the scientific research market. In exchange, MDxHealth will receive an upfront fee and royalties on sales of products incorporating the MSP technology. The firms did not disclose additional terms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.